Case Report

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Jamie A. Kmak, Nikita Agarwal, Yuting He, Andreas M. Heilmann, Vincent A. Miller, Jeffrey S. Ross, Sumanta Kumar Pal, Siraj M. Ali, Deepak Kilari

Keywords
PTEN · Prostate cancer · Everolimus · Castration resistant · mTOR

Abstract
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient’s tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.

Introduction
Prostate cancer (PC) is the most common non-cutaneous malignancy in men in the United States and accounts for over 26,000 deaths annually [1]. Androgen receptor (AR) signaling pathway inhibition has remained the cornerstone in the management of advanced PC for over 7 decades and identification of non-AR therapeutic targets in PC remains elusive. Prognosis for men who progress on AR-targeted therapy is dismal. Hence, there is an urgent and unmet need to identify non-AR targets which contain genomic alterations that would potentially respond to precision medicine strategies. Phosphatase and tensin homolog (PTEN) is a tumor
suppressor gene that has been targeted with success in patients with renal cell carcinoma and other malignancies; its inactivation leads to increased cell survival and proliferation because of hyperactivation of phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway [2, 3].

Here, we present the case of a patient with castrate-resistant prostate carcinoma (CRPC) who had failed multiple lines of treatment. He harbored a PTEN inactivating mutation and demonstrated an exceptional response to the mTOR inhibitor, everolimus (Afinitor; Novartis Pharma, Basel, Switzerland).

We also describe the genomic profiles from 261 consecutive cases of predominantly advanced PC harboring PTEN alterations and review the potential clinical utility of this class of alteration.

### Table 1. Variants detected in the patient's sample using comprehensive genomic profiling

| Reportable alterations | Variants of unknown significance |
|------------------------|---------------------------------|
| PTEN                   | N323fs*21                       |
| TP53                   | R273C                           |
| CDKN2A                 | loss                            |
| CDKN2B                 | loss                            |
| BMPR1A                 | V450M                           |
| CARD11                 | N91S                            |
| ERBB3                  | splice site 404_421+60del7B     |
| FLT4                   | V1355M                          |
| NTRK1                  | R744H                           |
| PIK3C2G                | V1313fs*8                       |
| ZNF703                 | H402_D403>PTHLGGSSCTCSAHD       |
| POLE                   | 5’ duplication                  |

**Variant of unknown significance**

| Variants of unknown significance |
|---------------------------------|
| BMPR1A V450M                    |
| CARD11 N91S                     |
| ERBB3 splice site 404_421+60del7B |
| FLT4 V1355M                     |
| NTRK1 R744H                     |
| PIK3C2G V1313fs*8              |
| ZNF703 H402_D403>PTHLGGSSCTCSAHD |
| POLE 5’ duplication             |

Case Report

A 67-year-old male was noted to have an elevated prostate-specific antigen (PSA) of 14 ng/mL during workup for nocturia. Further testing included a prostate biopsy that demonstrated Gleason grade 5 + 4 = 9 prostate adenocarcinoma in both lobes of the prostate and staging scans concerning for bone metastasis. He was started on a luteinizing hormone-releasing hormone agonist and bicalutamide. He had radiographic progression after only 7 months, and subsequent treatments included docetaxel, abiraterone, and cabazitaxel. Response to the above regimens was short-lived, with radiographic progression documented within 3 months on each line of treatment. Given treatment history including the rapid biochemical and radiographic progression, enzalutamide was not considered as the next appropriate line of treatment. Comprehensive genomic profiling (CGP) by a clinical next-generation sequencing hybrid capture-based assay using a formalin fixed, paraffin embedded prostatectomy specimen was performed by a CAP-accredited, CLIA-certified laboratory (Foundation Medicine, Cambridge, MA, USA) [4]. The test results showed that the tumor harbored an inactivating truncation mutation in PTEN N323fs*21 (see Table 1 for all the alterations detected). Based on these results, everolimus was started at a dose of 10 mg oral daily. During treatment, his PSA remained stable, staging scans (including a bone scan and computerized tomography) showed no changes and he experienced no additional symptoms related to his disease. The dose was reduced to 5 mg oral daily after 3 months of treatment due to fatigue and cytopenias. Secondary to drug-related fatigue, after a total duration of 8 months of therapy, everolimus was discontinued (Fig. 1; Table 1; Table 2).
Discussion

The present case underscores the potential clinical utility of genomic profiling in metastatic CRPC. The patient had received 3 of 6 approved therapies for CRPC, including docetaxel, cabazitaxel, and abiraterone. Sipuleucel-T, an autologous dendritic cell vaccine, was not considered appropriate as the drug is typically utilized in the pre-docetaxel space for asymptomatic or minimally symptomatic disease [5]. Radium-223, an alpha-emitting radio particle, could be considered for patients who are docetaxel refractory or ineligible [6]. This regimen was not chosen due to the rapidly rising PSA observed. Enzalutamide, a novel antiandrogen approved for use in the pre- and post-docetaxel setting based on the results from two phase III trials, was not considered due to emerging clinical data suggesting strong cross-resistance between enzalutamide and abiraterone [7–9].

All the above factors led to the decision to pursue CGP in the described patient, with the hope of identifying a pathway that could be potentially targeted with currently available drugs or with rational approaches in the context of a therapeutic clinical trial. It is estimated from the Cancer Genome Atlas (TCGA) analysis that homozygous deletions and inactivating mutations of PTEN occur in 40% and 5–10% of men with PC, respectively, but this data is based on a retrospective analysis of primary tumors, which may never progress to metastatic
disease [10]. We reviewed CGP results of 4,427 consecutive samples from patients with PS analyzed at Foundation Medicine during routine clinical care. Clinically relevant PTEN alterations inclusive of short variants, copy number losses, chromosomal rearrangements were detected in 1,423 patients (32.1%) with median age 66 years (range: 35–89). Homozygous deletion of PTEN was observed in 72.0% of these patients, with median age 67 (range: 39–89). Clinically relevant short variants and chromosomal rearrangements were detected in 25.0% of these patients, with median age 67 (range: 35–88) and 3.7% of patients with median age 65 (range: 47–86), respectively. 0.70% of patients had multiple PTEN alterations. Loss of heterozygosity in addition to a mutation in the other allele was recorded in 261 out of the 1,423 (18.3%) cases, including the index case. PTEN is thus bi-allelically inactivated in all 261 cases and the PI3K pathway is thus predicted to be activated. In contrast to the TCGA, the CGP described in this cohort is predominantly from heavily pretreated CRPC.

Functionally, PTEN is a tumor suppressor that negatively regulates the (PI3K)-AKT signaling axis. The PI3K and AR signaling pathways regulate each other through complex reciprocal feedback mechanisms. Upregulation of the mTOR pathway has been noted to confer resistance in CRPC cell lines and in CaP cells treated with ADT [11]. Similar crosstalk has been demonstrated between the estrogen receptor signaling pathway and the PI3K/AKT/mTOR pathway in breast cancer. Loss of PTEN expression was associated with inferior survival and shorter time on abiraterone treatment [12]. Loss of function hyperactivates mTORC1 signaling and is thought to confer sensitivity to rapamycin analogs such as everolimus.

Everolimus is FDA approved in the setting of advanced neuroendocrine cancers, hormone receptor-positive breast cancer, and renal cell carcinoma [13]. A phase II study examined everolimus in 37 patients with chemotherapy-naive mCRPC. A total of 13 patients (35.1%) had stable disease at 12 weeks. Two patients (5.4%) had PSA responses ≥50%. Notably, deletion of PTEN, although not specified as mono-allelic or bi-allelic, was associated with response to therapy, although this finding did not reach statistical significance [14]. A phase 2 clinical trial of everolimus and bicalutamide for CRPC demonstrated clinical activity; however, over 50% of patients had grade 3 or higher toxicity [15]. Similarly, several other studies also noted significant toxicity when PI3K/mTOR pathway inhibitors were combined with AR pathway inhibitors [16]. Several ongoing trials are combining novel antiandrogens (e.g., enzalutamide and ARN-509) with everolimus (NCT02106507; NCT02125084), although patients in most of these studies are not stratified by PTEN status. While the phase II experience provides evidence supporting everolimus in the context of CRPC prior to chemotherapy treatment, the case presented here suggests that everolimus can be effective in heavily treated disease in the context of a PTEN altered tumor. The prolonged period of radiographic disease stabilization (relative to three previously failed lines of treatment) suggests the possible broader efficacy of everolimus and the need to consider a sensitive and detailed assessment of the genomic status of PTEN for integration into the care of mCRPC patients. CGP can be used identify individuals with PTEN inactivating truncations, deletions, and homozygous losses to identify candidates for targeted therapy with everolimus and other PI3K-Akt-mTOR pathway inhibitors in development.

**Conclusion**

Everolimus is currently being investigated in chemotherapy-naive PC patients; however, our observation suggests clinical activity even in heavily treated mCRPC. Identification of PTEN inactivating truncations in mCRPC patients has potential clinical utility and warrants further investigation.
Statement of Ethics

Informed consent was obtained from the patient. The subject has given his written informed consent to publish his case. The authors have no ethical conflicts to disclose.

Disclosure Statement

J.A.K., N.A., Y.H., A.M.H., V.A.M., and J.S.R. are employees of and have equity interest in Foundation Medicine, Inc. V.A.M. is on the Board of Directors of Revolution Medicines and has received equity stake and compensation. S.K.P. has a research collaboration with Foundation Medicine Inc. S.M.A. is a former employee of Foundation Medicine, Inc., current SAB of Incysus Therapeutics, and does consulting for Revolution Medicines.

Funding Sources

None.

Author Contributions

All the authors equally contributed to the preparation of the manuscript.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
2. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84:166–72.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med. 2007 May 31;356(22):2271–81.
4. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023–31.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EF, Penson DF. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med. 2010 Jul 29;363(5):411–22.
6. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl J Med. 2013 Jul 18;369(3):213–23.
7. Scher HI, Fizazi K, Saad F, Saad F, Taplin ME, Sternberg CN, AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med. 2012 Sep 27;367(13):1187–97.
8. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med. 2014 Jul 31;371(5):424–33.
9. Cheng HH, Gulati R, Azad A, Naval R, Twardowski P, Vaishampayan UN. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122–7.
10. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H. The mutational landscape of prostate cancer. Eur Urol. 2013 Oct;64(4):567–76.
11. Wang Y, Mikhailova M, Bise S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27(56):7106–17.
12. Ferraldeschi R, Nava Rodrigues D, Riismaa R, Miranda S, Figueiredo I, Rescigno P. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015 Apr;67(4):795–802.
13. Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann New York Acad Sci. 2013 Jul;1291:14–32.
14 Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C., Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 2013 Jul; 64(1): 150–8.

15 Chow H, Ghosh PM, deVere White R, Evans CP, Dall’Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2017 Jun 15; 122(12): 1897–904.

16 Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M., A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer. Oncologist. 2017 May; 22(5): 503–e43.